Difference between revisions of "Globalisation:National Obesity Forum"
(→People) |
(→People) |
||
Line 20: | Line 20: | ||
==People== | ==People== | ||
− | *[[Trustees]] | + | *[[Globalisation: National Obesity Forum - Trustees]] |
− | *[[Funding]] | + | *[[Globalisation: National Obesity Forum - Funding]] |
− | *[[Collaborative Work]] | + | *[[Globalisation: National Obesity Forum - Collaborative Work]] |
==Views on tackling obesity== | ==Views on tackling obesity== |
Revision as of 08:50, 20 October 2010
Emma Patrick Christina McDonald Rachel Cunningham
http://www.nationalobesityforum.org.uk/
History
The National Obesity Forum was created in 2000 by a group of health professionals and is a registered charity (1109600).
The main aims of the NOF are to:
-Increase the public focus on obesity and develop more awareness about the health implications.
-To help educate more people on the topic of obesity and health from an earlier age.
-To encourage the Government to make tackling obesity a priority, in order to save the NHS money in future years.
People
Views on tackling obesity
The National Obesity Forum advocate many ways of tackling obesity.
-They advise increasing activity levels, and put importance on making exercise ‘fun’ and easy by focussing on ordinary activities such as gardening, shopping, and sports.
-They also advise making a personal plan to suit each individual.
-They provide information on how to have a healthy diet and put importance on portion control.
- Advice is also given on 'positive thinking' and how this can impact a person's ability to lose weight.
The NOF also back more drastic and often risky means of weight loss, including; very low calorie diets, medication, meal replacements, and even surgery.
With regards to weight loss medication (or 'Anti-Obesity Medication), the NOF mention two specific drugs - Sibutramine(Reductil) and Orlistat(Alli).
One of these drugs - Orlistat - was actually the first 'over the counter' weight loss drug available, and was produced by Glaxosmithkline, which is one of the NOFs parter organisations. [1]
Notes
- ↑ Orlistat, "Overweight and Obese Treatment - GlaxoSmithKline Receieves European Commission to Market Alli", Orlistat, 21 January 2009, accessed 19 October 2010